세계의 경구 고형 제제(OSD) 수탁제조 시장

Global Oral Solid Dosage Contract Manufacturing Market to Reach US$60.9 Billion by 2030

The global market for Oral Solid Dosage Contract Manufacturing estimated at US$41.7 Billion in the year 2024, is expected to reach US$60.9 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$30.0 Billion by the end of the analysis period. Growth in the Capsules segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.0 Billion While China is Forecast to Grow at 6.2% CAGR

The Oral Solid Dosage Contract Manufacturing market in the U.S. is estimated at US$11.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Oral Solid Dosage Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Contract Manufacturing for Oral Solid Dosage (OSD) Expanding Rapidly?

The oral solid dosage (OSD) contract manufacturing market is experiencing robust growth as pharmaceutical companies seek cost-effective and efficient production solutions. With the rising demand for tablets, capsules, and soft gels in both prescription and over-the-counter (OTC) markets, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) has become a strategic move for pharma companies.

Additionally, increasing regulatory requirements, pricing pressures, and the complexity of formulation development are prompting drug manufacturers to leverage the expertise of specialized CDMOs. The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further fueling demand for OSD pharmaceuticals, driving contract manufacturing partnerships.

How Are Technological Advancements Enhancing OSD Contract Manufacturing?

Innovation in manufacturing technology is reshaping the OSD contract manufacturing landscape. Continuous manufacturing, 3D printing, and advanced coating techniques are improving production efficiency, drug bioavailability, and patient compliance. High-speed compression and granulation techniques are enabling large-scale production with improved consistency and quality.

Another key advancement is the use of AI and machine learning in formulation optimization and predictive quality control. CDMOs are integrating smart manufacturing technologies to enhance real-time monitoring, reduce production errors, and ensure compliance with Good Manufacturing Practices (GMP). Additionally, the rise of fixed-dose combination (FDC) drugs is driving the need for more sophisticated OSD manufacturing capabilities.

Is the Demand for Specialty and High-Potency OSD Drugs Driving Market Trends?

The increasing focus on specialty pharmaceuticals and high-potency active pharmaceutical ingredients (HPAPIs) is reshaping contract manufacturing trends. CDMOs are investing in specialized containment facilities and advanced equipment to handle potent compounds used in oncology, immunosuppressants, and central nervous system (CNS) treatments.

Additionally, the demand for controlled-release and extended-release OSD formulations is growing, requiring CDMOs to expand their expertise in complex formulation techniques. The growing trend of personalized medicine is also influencing OSD manufacturing, as pharma companies explore targeted drug delivery solutions that cater to specific patient needs.

What’s Driving the Growth of the Oral Solid Dosage Contract Manufacturing Market?

The growth in the OSD contract manufacturing market is driven by several factors, including the rising demand for cost-effective drug production, increasing regulatory complexity, and the growing need for specialized formulation expertise. The shift toward continuous manufacturing and AI-driven quality control is further enhancing efficiency and scalability.

Additionally, the expansion of emerging markets and the increasing prevalence of chronic diseases are fueling demand for affordable and high-quality OSD pharmaceuticals. The rising trend of outsourcing drug production to CDMOs is expected to continue, ensuring steady market growth in the years ahead.

SCOPE OF STUDY:

The report analyzes the Oral Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Tablets, Capsules, Powders, Granules, Other Products); Mechanism (Controlled Release Mechanism, Immediate Release Mechanism, Delayed Release Mechanism); End-Use (Large Size Companies End-Use, Medium & Small Size Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• AbbVie Contract Manufacturing
• Aenova Group
• Alcami Corporation
• Almac Group
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• CMIC Holdings Co., Ltd.
• Corden Pharma International
• Delpharm
• Hetero Labs Limited
• Ind-Swift Laboratories Ltd.
• Jubilant Pharmova Limited
• Lonza Group AG
• NextPharma
• Patheon Pharma Services
• Piramal Pharma Solutions
• Recipharm AB
• Rubicon Research Pvt. Ltd.
• Siegfried Holding AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Oral Solid Dosage Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Pharmaceutical Outsourcing Trends Propel Growth of Contract Manufacturing Services
  • Surge in Generic Drug Consumption Drives Demand for Scalable Oral Solid Dosage Production
  • Strategic Focus on Core R&D Activities Strengthens Business Case for Outsourcing Manufacturing
  • Increasing Cost Pressures Among Mid-Sized Pharma Firms Expands Outsourcing Opportunities
  • Growing Demand for Orphan Drugs Unlocks Specialized Oral Solid Dosage Projects
  • Aging Global Population Sustains Long-Term Demand for Oral Solid Therapies
  • Rising Adoption of Fixed-Dose Combination Products Drives Innovation in Contract Manufacturing
  • Advancements in Continuous Manufacturing Technology Enhance Competitive Differentiation
  • Escalating Demand for High-Potency APIs Generates Opportunities for Specialized CMOs
  • Preference for Modified-Release Formulations Drives Adoption of Advanced Manufacturing Capabilities
  • Expansion of Emerging Pharma Markets Expands Addressable Market for Global CMOs
  • Implementation of Quality-by-Design (QbD) Practices Strengthens Regulatory Trust in CMOs
  • Technological Integration in Scale-Up and Tech Transfer Accelerates Client Acquisition
  • Growing Emphasis on Risk Mitigation and Operational Flexibility Fuels CMO Partnerships
  • Rise in FDA Approvals for Outsourced Drug Manufacturing Throws Spotlight on CMO Reliability
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oral Solid Dosage Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Powders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Powders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Granules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Granules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Medium & Small Size Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Medium & Small Size Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Large Size Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Large Size Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Controlled Release Mechanism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Controlled Release Mechanism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Immediate Release Mechanism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Immediate Release Mechanism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Delayed Release Mechanism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Delayed Release Mechanism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 30: USA Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 36: Canada Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• JAPAN
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 42: Japan Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• CHINA
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 48: China Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: China 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• EUROPE
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• FRANCE
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 58: France Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• GERMANY
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• ITALY
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• UNITED KINGDOM
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 76: UK Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• ASIA-PACIFIC
  • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030

IV. COMPETITION